AI device cleared by FDA to spot lesions during colonoscopyThe FDA has approved the first artificial intelligence-powered device that can be used to help identify colorectal lesions Share XAI device cleared by FDA to spot lesions during colonoscopyhttps://pharmaphorum.com/news/ai-device-cleared-by-fda-to-spot-lesions-during-colonoscopy/
NICE says yes to Braftovi combination for colorectal cancerTwo months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has Share XNICE says yes to Braftovi combination for colorectal cancerhttps://pharmaphorum.com/news/nice-says-yes-to-braftovi-combination-for-colorectal-cancer/
Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewIt’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal Share XMerck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewhttps://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerThe FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated Share XFDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/
Patient Insights: Colorectal CancerEvent planner and colorectal cancer survivor Kim Hall-Jackson tells us how she hopes to improve rates of diagnosis, Share XPatient Insights: Colorectal Cancerhttps://pharmaphorum.com/views-analysis-patients/patient-insights-colorectal-cancer/
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengeAmgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported Share XESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengehttps://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’A new trial has shown for the first time that a combination of three targeted therapies can improve Share XArray, Pierre Fabre bowel cancer therapy ‘could replace chemo’https://pharmaphorum.com/news/array-pierre-fabre-bowel-cancer-therapy-could-replace-chemo/
